anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
FIELD: medicine. ^ SUBSTANCE: invention relates to rehabilitating medicine, namely to physiotherapy. Method includes basic therapy, speleoclimatotherapy, foamy bubble baths. Daily on empty stomach one hour before breakfast, six day running with break on the seventh day, treatment with individually selected homeopathic monopreparations is performed. Treatment in speleoclimatic chamber is carried out in first half of the day, for 60 minutes, daily. After the end of speleotherapy session patient gets 250 ml of foamy oxygen cocktail from licorice on mineral water from spring 104-P of Psekupskoye deposit. Foamy bubble baths with dense extract of licorice root are taken in the second half of the day. Baths are alternated with days of discontinuous nornobaric hypoxytherapy with course of 12 procedures. ^ EFFECT: method reduces drug load on organism, slows disease progressing, increases remission duration, increases tolerance to physical exercise, improves respiratory functions. ^ 2 ex, 2 tbl
### Pregnancy Category C

Teratogenic effects were not observed in mice, rats, or rabbits when amitriptyline was given orally at doses of 2 to 40 mg/kg/day (up to 13 times the maximum recommended human dose 1). Studies in literature have shown amitriptyline to be teratogenic in mice and hamsters when given by various routes of administration at doses of 28 to 100 mg/kg/day (9 to 33 times the maximum recommended human dose), producing multiple malformations. Another study in the rat reported that an oral dose of 25 mg/kg/day (8 times the maximum recommended human dose) produced delays in ossification of fetal vertebral bodies without other signs of embryotoxicity. In rabbits, an oral dose of 60 mg/kg/day (20 times the maximum recommended human dose) was reported to cause incomplete ossification of cranial bones.

Amitriptyline has been shown to cross the placenta. Although a causal relationship has not been established, there have been a few reports of adverse events, including CNS effects, limb deformities, or developmental delay, in infants whose mothers had taken amitriptyline during pregnancy.

There are no adequate and well-controlled studies in pregnant women. Amitriptyline hydrochloride should be used during pregnancy only if the potential benefit to the mother justifies the potential risk to the fetus.

1 Based on a maximum recommended amitriptyline dose of 150 mg/day or 3 mg/kg/day for a 50 kg patient.
A wearable computing device is provided. The wearable computing device includes a, conductive housing and a printed circuit board at least partially disposed within the conductive housing. The wearable computing device further includes a slot antenna defined by a gap between the conductive housing and the printed circuit board. The wearable computing device includes a display screen electrically coupled to the printed circuit board. The wearable computing device includes a cover positioned on the display screen. The cover includes a top surface and a bottom surface. The wearable computing device includes a biometric sensor electrode positioned partially on the top surface of the cover. The biometric sensor at least partially wraps around a periphery of the cover.
The aim of present invention is to provide a procedure, a technique and a product able to induce the hair regrowth in the bald patches which have formed because of alopecia. Such a technique, does not have the disadvantages of the classic hair transplant. A further aim of the invention is that of providing a method with which it is possible to have new growth of hair on the bald patches on humans the use of the product. Furthermore, the aim is to provide a relatively simple method of application. The above aims can be reached by using the method based on the invention so that the hair grows again naturally. The invention, therefore, refers to the regrowth of hair, in alopecia.
Midazolam contains midazolam, a Schedule IV control substance.

Midazolam was actively self-administered in primate models used to assess the positive reinforcing effects of psychoactive drugs.

Midazolam produced physical dependence of a mild to moderate intensity in cynomolgus monkeys after 5 to 10 weeks of administration. Available data concerning the drug abuse and dependence potential of midazolam suggest that its abuse potential is at least equivalent to that of diazepam.

Withdrawal symptoms, similar in character to those noted with barbiturates and alcohol (convulsions, hallucinations, tremor, abdominal and muscle cramps, vomiting and sweating), have occurred following abrupt discontinuation of benzodiazepines, including midazolam. Abdominal distention, nausea, vomiting, and tachycardia are prominent symptoms of withdrawal in infants. The more severe withdrawal symptoms have usually been limited to those patients who had received excessive doses over an extended period of time. Generally milder withdrawal symptoms (e.g., dysphoria and insomnia) have been reported following abrupt discontinuance of benzodiazepines taken continuously at therapeutic levels for several months. Consequently, after extended therapy, abrupt discontinuation should generally be avoided and a gradual dosage tapering schedule followed. There is no consensus in the medical literature regarding tapering schedules; therefore, practitioners are advised to individualize therapy to meet patient’s needs. In some case reports, patients who have had severe withdrawal reactions due to abrupt discontinuation of high-dose long-term midazolam, have been successfully weaned off of midazolam over a period of several days.
We will complete the formative work collecting professional opinion to create and pilot the initial CHADIS Asthma Intervention module (CHADIS-AI), an innovative decision support system. CHADIS-AI content will be assembled and vetted by asthma experts and primary care providers (PCPs). Parent and teen focus groups will vet the content and language of the adherence materials and Care Portal. A system will also be established for points for patient participation, to give clinicians Maintenance of Certification (MOC) credit, and ongoing run chart reports of their patients' asthma status for continual Quality Improvement (QI) feedback. The resulting system will be pilot tested and refined by clinician feedback. Practices will be randomly assigned to intervention vs control. Control practices will use CHADIS for asthma care without the A-I module. Intervention practices will be further randomized to have remote coach support for patients or not. Outcomes will be examined of asthma severity/control, match of severity with guideline based medication management, numbers of Emergency Department (ED) visits, hospitalizations and oral steroid use. Effect of remote coaching will also be assessed.
This study is designed as a experiment study. In a medical center and breast ward, a randomized controlled trial was used to evaluate the effect of cryotherapy. Block sampling was adopted, and participants total 94 were included. Patients were randomly assigned to the croytherapy group (n=47) or the usual care group(n=47). Both hands and feet received cryotherapy, and the frequency was once every three weeks. Each cycle was 90-150 minutes, and the cycle was performed 4-8 times. The instrument included EPRTC QLQ-CIPN20, PNQ, and EORTC QLQ-C30. After 12-32 weeks, the cryotherapy received qualitative interviews to collect experience and perceptions. Quantitaitve data were constructed and analyzed with SPSS 20.0 version, and Chi-square test was used to detect the incidence of CIPN after three months. Mixed linear model was used to detect the severity of peripheral neuropathy symptoms and quality of life. Survival analysis was used to compare the occurrence time of peripheral neuropathy events between groups.
INTRODUCTION: Profound sexual health disparities exist for Black men who have sex with men (MSM) in the US South, including a high prevalence of sexually transmitted infections (STIs). Sexually transmitted infection prevention strategies beyond condoms are needed for Black MSM taking preexposure prophylaxis (PrEP).
METHODS: We conducted in-depth interviews with Black MSM taking PrEP in New Orleans, Louisiana. Informed by the Health Belief Model, we asked about participants' perceived susceptibility, severity, and concerns regarding STIs, and perceived benefits of STI prevention. We also asked about willingness to use various STI prevention strategies, including antibiotic prophylaxis. Interviews were audio-recorded and analyzed using applied thematic analysis.
RESULTS: We interviewed 24 Black MSM aged 18 to 36 years; half had a recent STI diagnosis. Most participants were concerned about receiving an STI diagnosis, noting shame or disappointment; physical effects were concerning but infrequently considered. Participants described being less likely to use condoms with routine partners or those taking PrEP. Most reported being willing to engage in each of the 6 prevention strategies discussed.
CONCLUSIONS: Black MSM taking PrEP voiced concern about STIs, and many noted that they infrequently use condoms. They were willing to engage in methods focused on preventing STIs on an individual or population level.
Chronic obstructive pulmonary disease (COPD) is a progressive lung disease for which there is no cure. Accumulating research results suggest a role for extracellular vesicles (EVs) in the pathogenesis of COPD. This study aimed to uncover the involvement of EVs and their molecular cargo in the progression of COPD by identification of EV-associated protein and microRNA (miRNA) profiles. We isolated EVs from the bronchial alveolar lavage fluid (BALF) of 18 patients with COPD and 11 healthy controls using size-exclusion chromatography. EV isolates were characterized using nanoparticle tracking analysis and protein content. Proteomic analysis revealed a higher abundance of 284 proteins (log2FC > 1) and a lower abundance of 3 proteins (log2FC < -1) in EVs derived from patients with COPD. Ingenuity pathway analysis showed that proteins enriched in COPD-associated EVs trigger inflammatory responses, including neutrophil degranulation. Variances in surface receptors and ligands associated with COPD EVs suggest a preferential interaction with alveolar cells. Small RNAseq analysis identified a higher abundance of ten miRNAs and a lower abundance of one miRNA in EVs from COPD versus controls (Basemean > 100, FDR < 0.05). Our data indicate that the molecular composition of EVs in the BALF of patients with COPD is altered compared to healthy control EVs. Several components in COPD EVs were identified that may perpetuate inflammation and alveolar tissue destruction.
Risk Summary 

Small amounts of contraceptive steroids and/or metabolites, including etonogestrel and ethinyl estradiol are transferred to human milk. Harmful effects have not been observed in breastfed infants exposed to CHCs through breast milk. CHCs can reduce milk production in breastfeeding mothers. This is less likely to occur once breastfeeding is well-established; however, it can occur at any time in some women. 

When possible, advise the nursing mother to use non-estrogen-containing contraception until she has completely weaned her child. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for EluRyng and any potential adverse effects on the breastfed child from EluRyng or from the underlying maternal condition.
The present invention relates to genes and their encoded proteins which regulate neurite growth and the diagnostic and therapeutic use of such proteins (termed herein neurite growth regulatory factors). The proteins of the present invention include central nervous system myelin associated proteins and metalloproteases associated with glioblastoma cells and other malignant tumors which can metastasize to the brain. The CNS myelin associated proteins inhibit neurite outgrowth in nerve cells and neuroblastoma cells, and can also inhibit fibroblast spreading. Such inhibitory proteins include a 35,000 dalton and a 250,000 dalton molecular weight protein and analogs, derivatives, and fragments thereof. The CNS myelin associated inhibitory proteins may be used in the treatment of malignant tumors. The present invention is also directed to antibodies to the CNS myelin associated proteins; such antibodies can be used in the diagnosis and therapies of nerve damage resulting from trauma, stroke, and degenerative disorders of the central nervous system. The metalloproteases of the invention have value in the treatment of nerve damage and of degenerative disorders of the nervous system.      The present invention is also directed to inhibitors of the metalloproteases. Such inhibitors in combination with the CNS myelin associated inhibitory proteins can be used in the treatment of malignant tumors.
Anthelmintic compositions comprise particles of a solid core of dimethyl-2, 2-dichlorovinyl phosphate (DDVP) and/or dimethyl-1, 2-dibromo-2, 2-dichloroethyl phosphate (Dibrom.) in solution in a solid polyvinyl chloride resin, coated with at least one coating of a mixture of one or more polyhydric alcohols with one or more natural gums, and overcoated with at least one surface coat of an edible, moisture-resistant material.  The polyvinyl chloride is preferably a hydrophobic resin of M.W. at least 5000.  Suitable polyhydric alcohols have a water solubility of at least 50% by weight, and provide such 50% solutions having a viscosity of about 40 centistokes at 20 DEG C.  Specific examples are propylene glycol; 1, 3-butanediol; 1, 4-butanediol; glycerol; 1, 2, 3-hexane triol; erythritol; arabitol; sorbitol; and dulcitol; and the hydrates thereof.  Natural gums mentioned are tragacanth, acacia, asafetida, guaiac, gamboge, guar, karaya, sweet gum, and gum arabic.  Edible moisture-resistant materials include shellac; shellac with n-butyl-stearate, with wool fat, or with cetyl alcohol, ammoniated shellac; cellulose acetate; collodion; formalized gelatin; salol; salol with shellac; and keratin.  The compositions are prepared by coating particles of polyvinyl chloride containing DDVP and/or Dibrom, such as are known in the prior art, with an aqueous solution of the polyhydric alcohol, and then dusting powdered natural gum over them, suitably in a rotating coating pan, under streams of warm air, successive coatings being applied to the required thickness.  The overcoating is applied, in a similar pan, by treating with a solution of the edible water-resistant material in a polar solvent (e.g. ethanol, methanol, iso-propanol, or acetone) and removing the solvent.  The finished product may be dusted with e.g. talcum.  Also within the scope of the invention are animal feed compositions comprising an animal feed mixed with the particles of the invention. The coatings stabilise the sustained release resin composition core to prevent deterioration on storage when admixed with a foodstuff.
PURPOSE:To prepare the titled external drug having excellent transcutaneous absorption, by dissolving or dispersing nicardipine hydrochloride useful as a vasodilator in a liquid mixture composed of a medium fatty acid glyceride, a propylene glycol and a urea compound, and forming the solution, etc. to an externally applicable drug. CONSTITUTION:The objective drug having the form suitable for external application can be prepared by dissolving or dispersing nicardipine hydrochloride in a liquid mixture obtained by compounding 1-15w/w% medium-chain fatty acid glyceride (e.g. monoglyceride or diglyceride of a 6-12C fatty acid), 1-15w/w% propylene glycol and 1-10w/w% urea compound (e.g. urea, ethylurea, etc.) preferably in an external drug. The solubility of nicardipine hydrochloride in individual medium-chain fatty acid glyceride, propylene glycol and urea compound is low; however, it can be increased, and the preparation and the transcutaneous absorption of the external drug can be improved by the use of the mixture of the above solvents.
This cohort will follow an interlocking design with Cohort 2 - Part A. Out of the 9 healthy subjects in this cohort, 3 subjects will receive placebo and 6 subjects will receive GSK2793660 according to randomization schedule in three single-dose study periods. Drug administration will be staggered over 2 days in each period. On Day 1, only 1 subject will receive GSK2793660 and 1 subject will receive placebo. The remaining subjects will be dosed on Day 2 of each treatment period assuming adequate safety from Day 1. Placebo administration and an escalation of GSK2793660 from 0.5 mg, to 3 mg, and 20 mg in the subsequent periods, will be done with a minimum washout period of 13 days between doses. If the target clinical dose is determined as being one of the doses administered to this cohort, they will have an additional study period for the administration of target clinical dose GSK2793660 following the standard Food and drug administration (FDA) high fat/high calorie meal.
The invention discloses a kind of calcium carbonate D to replenish the calcium for children 3 Chewable tablets and preparation method thereof, the chewable tablets are made of following component: calcium carbonate, vitamin D 3 Powder, maltodextrin, mannitol, magnesium stearate, essence.Preparation step is as follows: it is qualified that supplementary material needed for 1. is examined, spare after progress pre-treatment respectively；2. suspension is made in calcium carbonate, aqueous solution is made in maltodextrin, and the two is uniformly mixed；3. spray drying prepares the maltodextrin embedding composition granule of calcium carbonate；4. whole grain；5. total mix；6. measuring intermediates content, tabletting, bottling.The present invention uses spray drying technology, and the sand type of calcium carbonate can be effectively improved with maltodextrin embedding；Direct tablet compressing technology enormously simplifies production technology, and hardness is suitable for taking convenient for children's chewing.
OBJECTIVE: To analyze the effectiveness of preventive nursing interventions in patients on hemodialysis with arteriovenous fistulas (AVF) and the value in preventing complications of the AVF.
METHOD: It was a randomized controlled trial that enrolled 60 patients on hemodialysis treated in our hospital from April 2019 to May 2021. All enrollments were divided into control group (n = 30) and study group (n = 30) by random table methods. The control group received conventional nursing methods, while the study group received preventive nursing methods. The incidence of AVF complications, blood flow in the AVF, levels of anxiety and depression, quality of life and nursing satisfaction were assessed and compared.
RESULTS: The incidence of AVF complications in the study group after intervention was significantly lower than that in the control group. Blood flow in the AVF was much higher in the study group than in the control group. The anxiety and depression levels of patients in the study group after intervention were both lower than those of patients in the control group. Patients in the study group had a much better quality of life after intervention than those in the control group. The nursing satisfaction of patients in the study group after intervention was also higher than that of patients in the control group. In other words, patients in the study group were more satisfied with the way they had been cared for compared to those in the control group.
CONCLUSION: Preventive nursing interventions are effective in patients on hemodialysis. Not only do they reduce the incidence of AVF complications, they also improve blood flow in the AVF. In addition, they reduce such negative emotions as anxiety and depression, improves the patient's quality of life, as well as his or her satisfaction with care provision.
BACKGROUND: Enteric parasitic infections remain a major public health problem globally. Cryptosporidium spp., Cyclospora spp. and Giardia spp. are parasites that cause diarrhea in the general populations of both developed and developing countries. Information from molecular genetic studies on the speciation of these parasites and on the role of animals as vectors in disease transmission is lacking in Ghana. This study therefore investigated these diarrhea-causing parasites in humans, domestic rats and wildlife animals in Ghana using molecular tools.
METHODS: Fecal samples were collected from asymptomatic school children aged 9-12 years living around the Shai Hills Resource Reserve (tourist site), from wildlife (zebras, kobs, baboons, ostriches, bush rats and bush bucks) at the same site, from warthogs at the Mole National Park (tourist site) and from rats at the Madina Market (a popular vegetable market in Accra, Ghana. The 18S rRNA gene (18S rRNA) and 60-kDa glycoprotein gene (gp60) for Cryptosporidium spp., the glutamate dehydrogenase gene (gdh) for Giardia spp. and the 18S rDNA for Cyclospora spp. were analyzed in all samples by PCR and Sanger sequencing as markers of speciation and genetic diversity.
RESULTS: The parasite species identified in the fecal samples collected from humans and animals included the Cryptosporidium species C. hominis, C. muris, C. parvum, C. tyzzeri, C. meleagridis and C. andersoni; the Cyclopora species C. cayetanensis; and the Gardia species, G. lamblia and G. muris. For Cryptosporidium, the presence of the gp60 gene confirmed the finding of C. parvum (41%, 35/85 samples) and C. hominis (29%, 27/85 samples) in animal samples. Cyclospora cayetanensis was found in animal samples for the first time in Ghana. Only one human sample (5%, 1/20) but the majority of animal samples (58%, 51/88) had all three parasite species in the samples tested.
CONCLUSIONS: Based on these results of fecal sample testing for parasites, we conclude that animals and human share species of the three genera (Cryptosporidium, Cyclospora, Giardia), with the parasitic species mostly found in animals also found in human samples, and vice-versa. The presence of enteric parasites as mixed infections in asymptomatic humans and animal species indicates that they are reservoirs of infections. This is the first study to report the presence of C. cayetanensis and C. hominis in animals from Ghana. Our findings highlight the need for a detailed description of these parasites using high-throughput genetic tools to further understand these parasites and the neglected tropical diseases they cause in Ghana where such information is scanty.
Risk Summary

Based on published literature studies with L-asparaginase in pregnant animals, ASPARLAS can cause fetal harm when administered to a pregnant woman. There are no available data on ASPARLAS use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. In animal reproduction studies, intravenous administration of calaspargase pegol-mknl to pregnant rats during organogenesis at doses 0.2 to 1 times the maximum recommended human doses did not result in adverse developmental outcomes. Published literature studies in pregnant rabbits, however, suggest asparagine depletion may cause harm to the animal offspring (see Data). Advise pregnant women of the potential risk to a fetus.

In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies are 2 to 4% and 15 to 20%, respectively.

Data

Animal Data

In an embryo-fetal development study, calaspargase pegol-mknl was administered intravenously at doses of 75, 150, and 300 U/kg (0.2, 0.6 and 1 times the maximum recommended human dose, respectively, based on AUC) to pregnant rats during the period of organogenesis. Maternal toxicity of decreased body weight and food consumption was seen at all dose levels resulting in reductions in gravid uterine and placental weights, and slight reductions in fetal body weights. No evidence of structural abnormalities or embryo-fetal mortality were observed in this study at any of the doses tested. Published literature studies in which pregnant rabbits were administered L-asparaginase suggested harm to the animal offspring.